Department of Obstetrics and Gynecology, Corewell Health - William Beaumont University Hospital, Royal Oak, Michigan, USA.
Department of Care Management Analytics, Blue Cross Blue Shield of Michigan, Detroit, Michigan, USA.
Cancer Med. 2023 Oct;12(19):19644-19655. doi: 10.1002/cam4.6604. Epub 2023 Oct 3.
Pancreatic cancer (PC) is among the most lethal cancers. The lack of effective tools for early detection results in late tumor detection and, consequently, high mortality rate. Precision oncology aims to develop targeted individual treatments based on advanced computational approaches of omics data. Biomarkers, such as global alteration of cytosine (CpG) methylation, can be pivotal for these objectives. In this study, we performed DNA methylation profiling of pancreatic cancer patients using circulating cell-free DNA (cfDNA) and artificial intelligence (AI) including Deep Learning (DL) for minimally invasive detection to elucidate the epigenetic pathogenesis of PC.
The Illumina Infinium HD Assay was used for genome-wide DNA methylation profiling of cfDNA in treatment-naïve patients. Six AI algorithms were used to determine PC detection accuracy based on cytosine (CpG) methylation markers. Additional strategies for minimizing overfitting were employed. The molecular pathogenesis was interrogated using enrichment analysis.
In total, we identified 4556 significantly differentially methylated CpGs (q-value < 0.05; Bonferroni correction) in PC versus controls. Highly accurate PC detection was achieved with all 6 AI platforms (Area under the receiver operator characteristics curve [0.90-1.00]). For example, DL achieved AUC (95% CI): 1.00 (0.95-1.00), with a sensitivity and specificity of 100%. A separate modeling approach based on logistic regression-based yielded an AUC (95% CI) 1.0 (1.0-1.0) with a sensitivity and specificity of 100% for PC detection. The top four biological pathways that were epigenetically altered in PC and are known to be linked with cancer are discussed.
Using a minimally invasive approach, AI, and epigenetic analysis of circulating cfDNA, high predictive accuracy for PC was achieved. From a clinical perspective, our findings suggest that that early detection leading to improved overall survival may be achievable in the future.
胰腺癌(PC)是最致命的癌症之一。由于缺乏有效的早期检测工具,导致肿瘤晚期发现,因此死亡率很高。精准肿瘤学旨在基于组学数据的先进计算方法开发针对个体的靶向治疗。生物标志物,如胞嘧啶(CpG)甲基化的全局改变,可以成为这些目标的关键。在这项研究中,我们使用循环无细胞 DNA(cfDNA)和包括深度学习(DL)在内的人工智能(AI)对胰腺癌患者进行了 DNA 甲基化谱分析,以进行微创检测,阐明 PC 的表观发病机制。
使用 Illumina Infinium HD 分析对未经治疗的患者的 cfDNA 进行全基因组 DNA 甲基化谱分析。使用六种 AI 算法基于胞嘧啶(CpG)甲基化标志物来确定 PC 检测准确性。采用了额外的策略来最小化过度拟合。使用富集分析来研究分子发病机制。
总共在 PC 与对照组中鉴定出 4556 个显着差异甲基化的 CpG(q 值 < 0.05;Bonferroni 校正)。所有六种 AI 平台都实现了高度准确的 PC 检测(接收器操作特征曲线下的面积 [0.90-1.00])。例如,DL 实现 AUC(95%CI):1.00(0.95-1.00),灵敏度和特异性为 100%。基于逻辑回归的单独建模方法产生了 AUC(95%CI)1.0(1.0-1.0),PC 检测的灵敏度和特异性均为 100%。讨论了 PC 中发生表观遗传改变的前四个生物学途径,这些途径已知与癌症有关。
使用微创方法、AI 和对循环 cfDNA 的表观遗传学分析,实现了对 PC 的高预测准确性。从临床角度来看,我们的发现表明,未来可能实现早期检测,从而提高总体生存率。